Tranexamic acid for hyperacute primary intracerebral haemorrhage (TICH-3)

niversity of Nottingham0 个研究点目标入组 5,500 人开始时间: 2021年6月21日最近更新: 2024年9月9日

适应症

试验速览

暂无简介。

•Adult patients with ICH confirmed on brain imaging within 4.5 hours of symptom onset

•Current participant exclusion criteria as of 01/03/2023:
•1. Patient with a known indication for TXA treatment (e.g. traumatic brain injury)
•2. Patient with contraindication for TXA treatment
•3. Patient known to be taking therapeutic anticoagulation with warfarin or low molecular weight heparin at the time of enrolment. Patients taking direct oral anticoagulants can be included and are not excluded.
•4. Massive ICH for which haemostatic treatment seems futile (This would ordinarily be when haematoma volume is estimated as larger than 60ml)
•5. Severe coma (Glasgow Coma Scale <5)
•6. Decision was already taken for palliative (end of life) care with the withdrawal of active treatment
•Previous participant exclusion criteria:
•1. Indication for TXA
•2. Patient known to be taking anti-coagulation
•3. Glasgow Coma Scale (GCS) <5
•4. Estimated haematoma volume (HV) >60 ml
•5. Palliative care

发起方

niversity of Nottingham